{"id":56530,"date":"2026-02-06T21:47:35","date_gmt":"2026-02-06T13:47:35","guid":{"rendered":"https:\/\/flcube.com\/?p=56530"},"modified":"2026-02-06T21:47:36","modified_gmt":"2026-02-06T13:47:36","slug":"knature-biopharmaceutical-files-hong-kong-ipo-to-advance-mitochondrial-medicine-and-nad-therapeutics","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56530","title":{"rendered":"Knature Biopharmaceutical Files Hong Kong IPO to Advance Mitochondrial Medicine and NAD+ Therapeutics"},"content":{"rendered":"\n<p><strong>Knature Biopharmaceutical Co., Ltd.<\/strong>, a China\u2011based biopharma specializing in <strong>mitochondrial medicine<\/strong>, has submitted its <strong>initial public offering (IPO) filing<\/strong> to the <strong>Hong Kong Stock Exchange<\/strong>, seeking capital to accelerate R&amp;D and commercialization of <strong>NAD+\u2011based therapies<\/strong> targeting cardiovascular, neurodegenerative, and age\u2011related diseases.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-transaction-overview\">Transaction Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Knature Biopharmaceutical Co., Ltd.<\/td><\/tr><tr><td><strong>Listing Venue<\/strong><\/td><td>Hong Kong Stock Exchange (HKEX)<\/td><\/tr><tr><td><strong>Transaction Type<\/strong><\/td><td>Initial Public Offering (IPO)<\/td><\/tr><tr><td><strong>Filing Date<\/strong><\/td><td>Week of 02\u202fFeb\u202f2026<\/td><\/tr><tr><td><strong>Use of Proceeds<\/strong><\/td><td>R&amp;D expansion, production scale\u2011up, commercialization of mitochondrial therapeutics<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-scientific-platform-amp-therapeutic-focus\">Scientific Platform &amp; Therapeutic Focus<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Core Technology:<\/strong> <strong>Mitochondrial medicine<\/strong> platform addressing diseases rooted in <strong>mitochondrial dysfunction<\/strong><\/li>\n\n\n\n<li><strong>Lead Mechanism:<\/strong> <strong>NAD+ (nicotinamide adenine dinucleotide)<\/strong> biology applied to therapeutic intervention and healthspan extension<\/li>\n\n\n\n<li><strong>Target Indications:<\/strong><\/li>\n\n\n\n<li><strong>Cardiovascular diseases<\/strong> \u2013 Metabolic cardiac dysfunction and vascular aging<\/li>\n\n\n\n<li><strong>Neurodegenerative diseases<\/strong> \u2013 Mitochondrial decline in CNS disorders<\/li>\n\n\n\n<li><strong>Reproductive health<\/strong> \u2013 Oocyte and sperm quality optimization<\/li>\n\n\n\n<li><strong>Aging and longevity<\/strong> \u2013 Healthspan extension through cellular energy restoration<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-integrated-care-model\">Integrated Care Model<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Stage<\/th><th>Application<\/th><th>Strategic Value<\/th><\/tr><\/thead><tbody><tr><td><strong>Detection<\/strong><\/td><td>Biomarker identification for mitochondrial health status<\/td><td>Early patient stratification<\/td><\/tr><tr><td><strong>Intervention<\/strong><\/td><td>NAD+\u2011based therapeutic and nutritional protocols<\/td><td>Targeted treatment delivery<\/td><\/tr><tr><td><strong>Evaluation<\/strong><\/td><td>Clinical and digital health outcome monitoring<\/td><td>Real\u2011world evidence generation<\/td><\/tr><tr><td><strong>Re\u2011intervention<\/strong><\/td><td>Adaptive therapy adjustment based on biomarker feedback<\/td><td>Personalized longevity medicine<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-positioning-amp-investment-thesis\">Market Positioning &amp; Investment Thesis<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First\u2011Mover Advantage:<\/strong> Knature positions itself as a <strong>pioneer in mitochondrial medicine<\/strong> within China\u2019s biotech landscape, targeting the intersection of <strong>regenerative medicine and aging science<\/strong>\u2014sectors attracting significant global venture and public market capital.<\/li>\n\n\n\n<li><strong>NAD+ Commercialization Arc:<\/strong> The company\u2019s focus on <strong>NAD+ science<\/strong> aligns with validated longevity research (e.g., Sinclair Lab, ChromaDex) while differentiating through an integrated <strong>therapeutic + wellness<\/strong> approach spanning prescription drugs and health products.<\/li>\n\n\n\n<li><strong>Healthspan Economics:<\/strong> Targeting <strong>healthspan extension<\/strong> rather than disease\u2011specific indications alone opens dual revenue streams: pharmaceutical pipelines and consumer health products, mirroring the model of successful biotech\u2011to\u2011wellness transitions.<\/li>\n\n\n\n<li><strong>China Demographic Tailwind:<\/strong> Aging population dynamics and rising cardiovascular\/neurodegenerative disease burden create <strong>domestic market urgency<\/strong> for mitochondrial interventions, with potential for regulatory fast\u2011track given unmet medical needs.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape-amp-risk-factors\">Competitive Landscape &amp; Risk Factors<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Opportunity<\/th><th>Challenge<\/th><\/tr><\/thead><tbody><tr><td>Underserved mitochondrial disease market with limited approved therapies<\/td><td>Early\u2011stage platform with limited clinical\u2011stage assets at IPO<\/td><\/tr><tr><td>Crossover potential between pharma and wellness\/consumer health<\/td><td>NAD+ market crowded with supplement competitors; differentiation requires robust clinical data<\/td><\/tr><tr><td>HKEX listing provides international investor access and currency flexibility<\/td><td>Hong Kong biotech IPO market has seen volatility; valuation dependent on pipeline progress<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Knature Biopharmaceutical\u2019s IPO timeline, mitochondrial medicine platform development, and NAD+ therapeutic commercialization prospects. Actual results may differ due to regulatory review processes, clinical trial outcomes, and market conditions affecting Hong Kong listings.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/sehk26020501752_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of sehk26020501752_c.\"><\/object><a id=\"wp-block-file--media-99610213-f4dd-4cbd-b714-0ce0431305cb\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/sehk26020501752_c.pdf\">sehk26020501752_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/sehk26020501752_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-99610213-f4dd-4cbd-b714-0ce0431305cb\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Knature Biopharmaceutical Co., Ltd., a China\u2011based biopharma specializing in mitochondrial medicine, has submitted its initial&#8230;<\/p>\n","protected":false},"author":1,"featured_media":56533,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[72,4575],"class_list":["post-56530","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-ipo","tag-knature-biopharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Knature Biopharmaceutical Files Hong Kong IPO to Advance Mitochondrial Medicine and NAD+ Therapeutics - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Knature Biopharmaceutical Co., Ltd., a China\u2011based biopharma specializing in mitochondrial medicine, has submitted its initial public offering (IPO) filing to the Hong Kong Stock Exchange, seeking capital to accelerate R&amp;D and commercialization of NAD+\u2011based therapies targeting cardiovascular, neurodegenerative, and age\u2011related diseases.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=56530\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Knature Biopharmaceutical Files Hong Kong IPO to Advance Mitochondrial Medicine and NAD+ Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Knature Biopharmaceutical Co., Ltd., a China\u2011based biopharma specializing in mitochondrial medicine, has submitted its initial public offering (IPO) filing to the Hong Kong Stock Exchange, seeking capital to accelerate R&amp;D and commercialization of NAD+\u2011based therapies targeting cardiovascular, neurodegenerative, and age\u2011related diseases.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=56530\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-06T13:47:35+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-06T13:47:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0607.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56530#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56530\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Knature Biopharmaceutical Files Hong Kong IPO to Advance Mitochondrial Medicine and NAD+ Therapeutics\",\"datePublished\":\"2026-02-06T13:47:35+00:00\",\"dateModified\":\"2026-02-06T13:47:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56530\"},\"wordCount\":462,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56530#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0607.webp\",\"keywords\":[\"IPO\",\"Knature Biopharmaceutical\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56530#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56530\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=56530\",\"name\":\"Knature Biopharmaceutical Files Hong Kong IPO to Advance Mitochondrial Medicine and NAD+ Therapeutics - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56530#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56530#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0607.webp\",\"datePublished\":\"2026-02-06T13:47:35+00:00\",\"dateModified\":\"2026-02-06T13:47:36+00:00\",\"description\":\"Knature Biopharmaceutical Co., Ltd., a China\u2011based biopharma specializing in mitochondrial medicine, has submitted its initial public offering (IPO) filing to the Hong Kong Stock Exchange, seeking capital to accelerate R&D and commercialization of NAD+\u2011based therapies targeting cardiovascular, neurodegenerative, and age\u2011related diseases.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56530#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56530\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56530#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0607.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0607.webp\",\"width\":1080,\"height\":608,\"caption\":\"Knature Biopharmaceutical Files Hong Kong IPO to Advance Mitochondrial Medicine and NAD+ Therapeutics\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56530#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Knature Biopharmaceutical Files Hong Kong IPO to Advance Mitochondrial Medicine and NAD+ Therapeutics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Knature Biopharmaceutical Files Hong Kong IPO to Advance Mitochondrial Medicine and NAD+ Therapeutics - Insight, China&#039;s Pharmaceutical Industry","description":"Knature Biopharmaceutical Co., Ltd., a China\u2011based biopharma specializing in mitochondrial medicine, has submitted its initial public offering (IPO) filing to the Hong Kong Stock Exchange, seeking capital to accelerate R&D and commercialization of NAD+\u2011based therapies targeting cardiovascular, neurodegenerative, and age\u2011related diseases.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=56530","og_locale":"en_US","og_type":"article","og_title":"Knature Biopharmaceutical Files Hong Kong IPO to Advance Mitochondrial Medicine and NAD+ Therapeutics","og_description":"Knature Biopharmaceutical Co., Ltd., a China\u2011based biopharma specializing in mitochondrial medicine, has submitted its initial public offering (IPO) filing to the Hong Kong Stock Exchange, seeking capital to accelerate R&D and commercialization of NAD+\u2011based therapies targeting cardiovascular, neurodegenerative, and age\u2011related diseases.","og_url":"https:\/\/flcube.com\/?p=56530","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-06T13:47:35+00:00","article_modified_time":"2026-02-06T13:47:36+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0607.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=56530#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=56530"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Knature Biopharmaceutical Files Hong Kong IPO to Advance Mitochondrial Medicine and NAD+ Therapeutics","datePublished":"2026-02-06T13:47:35+00:00","dateModified":"2026-02-06T13:47:36+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=56530"},"wordCount":462,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=56530#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0607.webp","keywords":["IPO","Knature Biopharmaceutical"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=56530#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=56530","url":"https:\/\/flcube.com\/?p=56530","name":"Knature Biopharmaceutical Files Hong Kong IPO to Advance Mitochondrial Medicine and NAD+ Therapeutics - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=56530#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=56530#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0607.webp","datePublished":"2026-02-06T13:47:35+00:00","dateModified":"2026-02-06T13:47:36+00:00","description":"Knature Biopharmaceutical Co., Ltd., a China\u2011based biopharma specializing in mitochondrial medicine, has submitted its initial public offering (IPO) filing to the Hong Kong Stock Exchange, seeking capital to accelerate R&D and commercialization of NAD+\u2011based therapies targeting cardiovascular, neurodegenerative, and age\u2011related diseases.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=56530#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=56530"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=56530#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0607.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0607.webp","width":1080,"height":608,"caption":"Knature Biopharmaceutical Files Hong Kong IPO to Advance Mitochondrial Medicine and NAD+ Therapeutics"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=56530#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Knature Biopharmaceutical Files Hong Kong IPO to Advance Mitochondrial Medicine and NAD+ Therapeutics"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0607.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56530","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=56530"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56530\/revisions"}],"predecessor-version":[{"id":56534,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56530\/revisions\/56534"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/56533"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=56530"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=56530"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=56530"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}